IceCure Medical Awaits FDA Decision on ProSense® for Breast Cancer

Icecure Medical ( (ICCM) ) has issued an announcement.

On May 28, 2025, IceCure Medical reported its financial results for the first quarter of 2025, highlighting a strategic focus on gaining FDA marketing authorization for its ProSense® system for treating early-stage low-risk breast cancer in women over 70. The company has submitted a post-market study plan to the FDA and anticipates a positive decision that could significantly impact its market presence. Despite a slight decline in revenue, IceCure is experiencing increased interest in North America and secured a $2 million loan from its largest investor, reflecting confidence in its technology. The company is also awaiting regulatory decisions in Japan and Israel and continues to gain traction through various international medical conferences.

The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s overall score reflects its ongoing financial and profitability challenges, balanced by positive sales growth and potential regulatory catalysts. Key strengths include sales momentum and FDA panel support, while high net losses and cash flow issues remain significant concerns.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical, listed on Nasdaq as ICCM, develops and markets advanced cryoablation therapy systems using liquid nitrogen for tumor treatment, focusing on breast, kidney, bone, and lung cancer. Their flagship product, ProSense®, offers a minimally invasive alternative to surgical tumor removal and is marketed globally.

Average Trading Volume: 264,734

Technical Sentiment Signal: Sell

Current Market Cap: $63.92M

Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.